@article{b17e392195bc4b3ba1eba113c961ca6e,
title = "Author Response: Local Geographic Atrophy Growth Rates Not Influenced by Close Proximity to Non-Exudative Type 1 Macular Neovascularization",
author = "Omer Trivizki and Moult, \{Eric Michael\} and Liang Wang and Prashanth Iyer and Yingying Shi and Giovanni Gregori and William Feuer and Fujimoto, \{James G.\} and Rosenfeld, \{Philip J.\}",
note = "Funding Information: Disclosure: E.M. Moult, VISTA-OCTA (P). Philip Rosenfeld and Giovanni Gregori receive research support from Carl Zeiss Meditec, Inc. and the University of Miami co-owns a patent that is licensed to Carl Zeiss Meditec, Inc. Philip Rosenfeld also receives research support from Stealth BioTherapeutics. He is a consultant for Apellis, Biogen, Boehringer-Ingelheim, Carl Zeiss Meditec, Biogen, Chengdu Kanghong Biotech, EyePoint, Ocunexus Therapeutics, Ocudyne, and Unity Biotechnology. Philip Rosenfeld has equity interest in Apellis, Valitor, Verana Health, and Ocudyne; J.G. Fujimoto, Optovue (I, P), Topcon (F), VISTA-OCTA (P)",
year = "2022",
month = may,
doi = "10.1167/iovs.63.5.11",
language = "אנגלית",
volume = "63",
journal = "Investigative Ophthalmology and Visual Science",
issn = "0146-0404",
publisher = "Association for Research in Vision and Ophthalmology Inc.",
number = "5",
}